Background: Patients with classic congenital adrenal hyperplasia (CAH) due to CYP21 deficiency are treated with supraphysiological doses of glucocorticoids to suppress elevated androgen production. This implies also side effects of high-dose glucocorticoids, possibly leading to iatrogenic Cushing's syndrome. Bilateral adrenalectomy has been suggested as the ultimate therapy in severe cases, when insufficient androgen suppression was obtained despite high glucocorticoid doses. Usually, ACTH levels rise after bilateral adrenalectomy, and this could imply an increased risk for the development of ectopic adrenal rests. In female CAH patients ovarian adrenal rests are not commonly detected by conventional radiological techniques. Methods: We report the case of an adult female CAH patient who underwent bilateral adrenalectomy in early puberty because of poorly controlled CAH. Results and Conclusions: Several years after surgery, she developed secondary amenorrhea and hair loss as a result of androgen overproduction in ovarian adrenal rests that appeared to be detectable only by pelvic venous sampling. After unilateral oophorectomy androgen levels normalized.

Keywords:
Congenital adrenal hyperplasia, Adrenalectomy, Adrenal rests, Hyperandrogenism, Pelvic venous sampling
1.
Merke DP, Bornstein SR: Congenital adrenal hyperplasia. Lancet 2005;365:2125-2136.
2.
Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC: Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:4133-4160.
3.
Muthusamy K, Elamin MB, Smushkin G, Murad MH, Lampropulos JF, Elamin KB, et al: Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J Clin Endocrinol Metab 2010;95:4161-4172.
4.
Bonfig W, Bechtold S, Schmidt H, Knor D, Schwarz HP: Reduced final height outcome in congenital adrenal hyperplasia and prednisone treatment: deceleration of growth velocity during puberty. J Clin Endocrinol Metab 2007;92:1635-1639.
5.
Claahsen-van der Grinten HL, Stikkelbroeck NM, Otten BJ, Hermus AR: Congenital adrenal hyperplasia - pharmacologic interventions from the prenatal phase to adulthood. Pharmacol Ther 2011;132:1-14.
6.
Van Wyk JJ, Ritzen EM: The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003;88:2993-2998.
7.
Claahsen-van der Grinten HL, Hermus AR, Otten BJ: Testicular adrenal rest tumours in congenital adrenal hyperplasia. Int J Pediatr Endocrinol 2009:624823.
8.
Claahsen-van der Grinten HL, Otten BJ, Sweep FC, Span PN, Ross HA, Meuleman EJ, Hermus AR: Testicular tumors in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency show functional features of adrenocortical tissue. J Clin Endocrinol Metab 2007;92:3674-3680.
9.
Stikkelbroeck NM, Hermus AR, Schouten D, Suliman HM, Jager GJ, Braat DD, Otten BJ: Prevalence of ovarian adrenal rest tumours and polycystic ovaries in females with congenital adrenal hyperplasia: results of ultrasonography and MR imaging. Eur Radiol 2004;14:1802-1806.
10.
Mooij CF, Kroese JM, Claahsen-van der Grinten HL, Tack CJ, Hermus AR: Unfavourable trends in cardiovascular and metabolic risk in paediatric and adult patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2010;73:137-146.
11.
Charmandari E, Chrousos GP, Merke DP: Adrenocorticotropin hypersecretion and pituitary microadenoma following bilateral adrenalectomy in a patient with classic 21-hydroxylase deficiency. J Pediatr Endocrinol Metab 2005;18:97-101.
12.
Warinner SA, Zimmerman D, Thompson GB, Grant CS: Study of three patients with congenital adrenal hyperplasia treated by bilateral adrenalectomy. World J Surg 2000;24:1347-1352.
13.
Meyers RL, Grua JR: Bilateral laparoscopic adrenalectomy: a new treatment for difficult cases of congenital adrenal hyperplasia. J Pediatr Surg 2000;35:1586-1590.
14.
Stikkelbroeck NM, Otten BJ, Pasic A, Jager GJ, Sweep CG, Noordam K, Hermus AR: High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001;86:5721-5728.
15.
Claahsen-van der Grinten HL, Sweep FC, Blickman JG, Hermus AR, Otten BJ: Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 2007;157:339-344.
16.
Claahsen-van der Grinten HL, Otten BJ, Hermus AR, Sweep FC, Hulsbergen-van de Kaa CA: Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause severe testicular damage. Fertil Steril 2008;89:597-601.
17.
Claahsen-van der Grinten HL, Stikkelbroeck NM, Sweep CG, Hermus AR, Otten BJ: Fertility in patients with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2006;19:677-685.
18.
Clark RV, Albertson BD, Munabi A, Cassorla F, Aguilera G, Warren DW, Sherins RJ, Loriaux DL: Steroidogenic enzyme activities, morphology, and receptor studies of a testicular adrenal rest in a patient with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1990;70:1408-1413.
19.
Al Ahmadie HA, Stanek J, Liu J, Mangu PN, Niemann T, Young RH: Ovarian ‘tumor' of the adrenogenital syndrome - the first reported case. Am J Surg Pathol 2001;25:1443-1450.
20.
Tiosano D, Vlodavsky E, Filmar S, Weiner Z, Goldsher D, Bar-Shalom R: Ovarian adrenal rest tumor in a congenital adrenal hyperplasia patient with adrenocorticotropin hypersecretion following adrenalectomy. Horm Res 2010;74:223-228.
21.
Russo G, Paesano P, Taccagni G, Del Maschio A, Chiumello G: Ovarian adrenal-like tissue in congenital adrenal hyperplasia. N Engl J Med 1998;339:853-854.
22.
Zachmann M, Manella B, Kempken B, Knorr-Muerset G, Atares M, Prader A: Ovarian steroidogenesis in an adrenalectomized girl with 21-hydroxylase deficiency. Clin Endocrinol 1984;21:575-582.
23.
Claahsen-van der Grinten HL, Hulsbergen-van de Kaa CA, Otten BJ: Ovarian adrenal rest tissue in congenital adrenal hyperplasia - a patient report. J Pediatr Endocrinol Metab 2006;19:177-182.
24.
Lila AR, Malhotra G, Sarathi V, Bandgar TR, Menon PS, Shah NS: Localization of remnant and ectopic adrenal tissues with cosyntropin-stimulated 18F-FDG-PET/CT in a patient with Nelson syndrome with persistent hypercortisolism. J Clin Endocrinol Metab 2010;95:5172-5173.
25.
Crocker MK, Barak S, Millo CM, Beall SA, Niyyati M, Chang R, Avila NA, Van Ryzin C, Segars J, Quezado M, Merke DP: Use of PET/CT with cosyntropin stimulation to identify and localize adrenal rest tissue following adrenalectomy in a woman with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2012;97:E2084-E2089.
26.
Dickerson RD, Putman MJ, Black ME, Pinto KR, Diamond NG, Marynick S, Pinto AB: Selective ovarian vein sampling to localize a Leydig cell tumor. Fertil Steril 2005;84:218.
27.
Ozgun MT, Batukan C, Turkyilmaz C, Dolanbay M, Mavili E: Selective ovarian vein sampling can be crucial to localize a Leydig cell tumor: an unusual case in a postmenopausal woman. Maturitas 2008;61:278-280.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.